Healthcare / BiotechnologyNasdaqCM
$5.07
+0.35 (+7.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-22.0M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$97M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-311.4%
↓Gross Margin
N/A
•Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-34.2M · FCF $-28.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-34.2M | $-34.2M | $-29.0M | $-23.9M | $-39.6M |
| EBITDA | $-31.8M | $-31.8M | $-25.8M | $-20.4M | $-37.2M |
| EPS | -2.09 | -2.09 | -4.91 | -16.99 | -60.90 |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 1.25 | -5.62 | 2.36 |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-28.1M | $-28.1M | $-22.0M | $-17.4M | $-36.1M |
| Returns | |||||
| ROE | -311.4% | -311.4% | -377.7% | 1138.6% | -678.6% |
| Valuation | |||||
| P/B | 7.56 | 7.56 | 2.35 | — | 2.53 |
| Growth & Yield | |||||
| EPS Growth | 57.4% | 57.4% | 71.1% | 72.1% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+81.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.91 → -2.09
Residual
+81.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.